Celgene

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018 Juno Therapeutics was acquired by Celgene for $9 billion.

Juno Therapeutics

Lenalidomide (trade name Revlimid) is a derivative of thalidomide introduced in 2004.  It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Along with several other drugs developed in recent years, lenalidomide has significantly improved overall survival in myeloma (which formerly carried a poor prognosis), although toxicity remains an issue for users. It costs $163,381 per year for the average patient.

Revlimid

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.   There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.   In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Bristol-Myers

Caesars Entertainment

Match Group

New Relic

Bristol-Myers Squibb, Celgene, Caesars Entertainment, Match Group and New Relic are our top stock trades for Tuesday.

5 Top Stock Trades for Tuesday

The $74 billion merger of Bristol-Myers Squibb and Celgene has been delayed as FTC pushback spurred Celgene to divest a major psoriasis drug.

Bristol-Myers deal to acquire Juno parent Celgene delayed amid FTC concerns

Shares of Bristol-Myers Squibb plunged Monday after announcing that the target closing date for the proposed acquisition of Celgene has been pushed back and that the deal will include a divestiture of Otezla, a psoriasis drug.

Bristol-Myers Squibb, Celgene slide following news of delayed deal and psoriasis drug divestment

Uncertainty over Bristol-Myers Squibb Co (NYSE: BMY)'s impending deal to acquire Celgene Corporation (NASDAQ: CELG) and an adverse clinical trial readout were dragging the shares of the large-cap pharma company lower Monday.

Bristol-Myers Slips As Regulatory Hiccups Delay Celgene Deal; Liver Cancer Study Faces Setback

Celgene will have to divest its blockbuster drug Otezla in order to satisfy drug regulators before completing its merger with Bristol-Myers Squibb, the biopharma companies said Monday.
The post Bristol-Myers Plans To Divest Celgene Blockbuster To Satisfy Regulators appeared first on Investor's Business Daily.

Bristol-Myers Plans To Divest Celgene Blockbuster To Satisfy Regulators

Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).

Bristol to divest Celgene's psoriasis treatment in FTC clearance push

Bristol-Myers Squibb Co. BMY, +0.92% said Monday a late-stage study of its Opdivo as a treatment for a type of liver cancer failed to meet its main goals.

Bristol-Myers offers update on liver cancer trial, to sell Otzela to hasten close of Celgene deal

Anadarko Petroleum

Copart

Tyson Foods

Xerox

As the S&P 500 hits new high, we have presented a bunch of stocks that have easily led the way gaining more than 45%, and will continue to outperform heading into the second half.

5 Best-Performing S&P 500 Stocks So Far This Year

AbbVie

Novartis

These follow-on drugs are on a path to upend the current standards of care.

3 Drugs Under FDA Review With Blockbuster Potential

Bristol-Myers Squibb announced its plan to acquire Celgene more than 6 months ago. The deal has since been approved by shareholders from both companies.

Bristol-Myers Squibb And Celgene - On The Path To A Valuable Combination

Shareholders get an all-or-nothing $9 contingent value right (CVR) when the acquisition closes.

What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?

Amgen

Gilead Sciences

Johnson & Johnson

Pfizer

There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

Big Drugmakers That May Tread the M&A Path After Pfizer

Citigroup

Designer Brands

Zions Bancorp

Earnings yield is very effective for determining undervalued stocks.

Four High Earnings Yield Stocks to Strengthen Your Portfolio

The clock is ticking for Celgene's acquisition by Bristol-Myers Squibb. But is Celgene still a stock worth buying?

Is It Too Late to Buy Celgene Stock?

Merck

Each of these drugs is forecast to rake in at least $9.5 billion in 2024. Investors looking to profit should pay attention to the pharmaceutical giants that sell them.

5 Biggest Blockbuster Drugs of the Future

Celgene finally gets the FDA on board with its regulatory application for potential approval of ozanimod to treat relapsing forms of multiple sclerosis; PDUFA date set for March 25, 2020.

Celgene's Long Journey Through Regulatory Filings For Ozanimod Might Finally Pay Off

Vertex Pharmaceuticals

New blockbusters could be on the way for five drugmakers.

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

CELG vs. VRTX: Which Stock Is the Better Value Option?

CELG or VRTX: Which Is the Better Value Stock Right Now?

Northrop Grumman

PepsiCo

ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

Top 5 ROE Stocks to Buy as US-Mexico Trade Concerns Abate

Arconic

Amdocs

Target

Investors target stocks that are on a bullish run of late. Stocks witnessing price strength show a high chance of carrying the winning momentum forward.

5 Solid Stocks Near 52-Week High Promise to Touch Peak Point

Biogen

Teva Pharmaceutical

The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

Celgene's Filing for Ozanimod Accepted for Review in US/EU

Takeda Pharmaceutical

Telesis Bio Inc

The most prominent positions in Seth Klarman (Trades, Portfolio) equity portfolio are well-known and covered by the financial media.

Seth Klarman's Favorite Biotech Positions

Shareholders are hoping the acquisition and new leadership will energize the stock price.

Management Changes Intended to Boost Bristol-Myers Squibb After Celgene Deal

Acceleron Pharma

Celgene (CELG) along with partner Acceleron submits application for luspatercept to the FDA.

Celgene & Acceleron's BLA for Luspatercept Accepted by FDA

Bristol-Myers stock is cheap, but investors are sitting on the sidelines ahead of the Celgene merger, an analyst said Wednesday. The deal is now expected to close late in the third quarter.

News for Celgene Stock (CELG)